Form 4: Catalyst Pharma Director Converts RSUs to Common Stock

Catalyst Pharmaceuticals Director Donald A. Denkhaus converted 1,334 restricted stock units into common stock on December 29, 2025, increasing his direct common stock holdings.

Summary

• Donald A. Denkhaus, a Director at Catalyst Pharmaceuticals, Inc. (CPRX), reported a transaction on December 29, 2025.
• The transaction involved the conversion of 1,334 Restricted Stock Units (RSUs) into an equal number of common stock shares.
• Following this conversion, direct beneficial ownership of common stock increased to 498,773 shares.
• The RSUs converted were part of a pre-scheduled vesting plan, with the final tranche vesting on December 27, 2025.
• After the transaction, 178,163 Restricted Stock Units remain beneficially owned directly.

Sentiment

Score: 7

Explanation: The conversion of restricted stock units into common stock by a director is a routine, pre-scheduled event that increases the director's direct equity stake, generally viewed as a neutral to slightly positive sign of continued commitment.

Positives

• Director Donald A. Denkhaus increased his direct beneficial ownership of Catalyst Pharmaceuticals common stock by 1,334 shares through the conversion of Restricted Stock Units.
• The conversion demonstrates continued alignment of the director's interests with those of shareholders as he holds more direct equity.

Negatives

• No negative information is presented in this routine insider transaction report.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This routine insider transaction by a director does not provide sufficient information to analyze broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders may view the director's increased direct common stock ownership as a positive signal of continued alignment and confidence in the company.

Key Dates

Recommendation

The filing details a routine conversion of restricted stock units into common stock by a director, which is a pre-scheduled event and does not provide new information to alter an investment thesis. It reflects continued ownership but not a new investment decision.

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, RSU Conversion, Stock Ownership, Director